Who Paid My Doc
Phase III Renal Outcomes
Research payments
$567,967
Through program year 2025, $567,967 in research payments was reported against Phase III Renal Outcomes, across 61 payments.
- Paid by (largest first)
- Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $136,585 | 14 |
| 2024 | Research | $431,381 | 47 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Danny Sugimoto Forest Park, IL Named on 5 payments
- Bradley Eilerman Florence, KY Named on 5 payments
- Kianoosh Kaveh Port Charlotte, FL Named on 4 payments
- Pusadee Suchinda Sumter, SC Named on 2 payments
- Carlo Castillo Huntsville, AL Named on 2 payments
- Sucharit Joshi Portsmouth, NH Named on 2 payments
- Lance Sloan Lufkin, TX Named on 2 payments
- Larissa Kruger Gomes East Providence, RI Named on 1 payment
- Minesh Rajpal Peoria, AZ Named on 1 payment
- Gregory Greenwood Winston-Salem, NC Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.